Transcript of podcast by Tabassome Simon on Clinical Pharmacology and FAST-MI

Listen to podcast of Professor Tabassome Simon discussing Clinical Pharmacology and the FAST-MI Registry.

DS     I am in Geneva at the 11^th EACPT Congress with Professor Tabassome Simon.  

FAST-MI co-author Ziad Mallat with EACPT Chair-Elect Tabassome Simon & EACPT Secretary Donald Singer

Tabassome, would you comment on the ways in which your expertise as a Clinical Pharmacologist has contributed to the success of the Fast-MI Registry.

TS      Since I am a Clinical Pharmacologist, I would just focus on papers emerged from my interests as a clinical pharmacologist.

What is great about being all together in different fields, is talking together.  We have different visions of the same issue and that gives us really strength, our way of looking at disease and that is what clinical pharmacology is about. 

One example of which we are very proud was the paper that we did that was published in the New England Journal of Medicine regarding the impact of polymorphisms for metabolism and transporters ABCB1 and CYP2C19 onoutcomes for those who were receiving clopidogrel. 

That was the first paper that we did together, with another team from the United States who did a trial called Triton with prasugrel and clopidogrel.  Both papers were published in the New England Journal of Medicine and that was a huge hit in 2009.  Later on, several other papers were focussed on this genotyping process, including with the Plato trial with ticagrelor.

One further aspect that FAST-MI brought us [was recording] concomitant drugs which were usually not taken into account in registries, in particular for PPIs -  proton pump inhibitors. We had that [information] and so we could look also at the impact of drug interactions. We published that in Circulation.

Later on we did several papers with Ziad Mallat and other colleagues regarding the impact of lipases such as sPLA2, both [from studies] in blood but also [from studies of] Mendelian randomisation. The paper is in press actually, in the Journal of American College of Cardiology, and will be published soon. Another paper regarding BAFF targeting B cells will be published in Nature Medicine this year.

DS     Tabassome Simon, thank you very much.

Selected references from FAST-MI publications

Simon T., Verstuyft C., Mary-Krause M, Quteineh L., Drouet E., Meneveau N., Steg P.G., Ferrieres J., Danchin N., Becquemont L., for the French Registry of Acute ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009;360 : 363-75

Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, Khalife K, Goldstein P, Cattan S, Vaur L, Cambou JP, Ferrières J, Danchin N; USIK USIC 2000 Investigators; FAST MI Investigators. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998-1006.

Simon T, Steg Ph G, Gilard M, Blanchard D,  Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre Th, Drouet E , Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N. Clinical events as a function of PPI use, clopidogrel use and CYP2C19 genotype in a large nationwide cohort of acute myocardial infarction: Results from the FAST-MI Registry; Circulation 2011, 123:474-482

Danchin N, Coste P, Ferrieres J, STEG G, Cottin Y, Blanchard D, Belle L, Ritz B, Kirkorian G, Angioi M, Sans Ph, Charbonnier B, Eltchaninoff H, Gueret P, Khalife K, Asseman Ph , Puel J, Cambou J-P, Simon T. A comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary PCI for ST segment elevation acute myocardial infarction. Circulation 2008; 118: 268-276

Lind L.†, Simon T. †, Johansson L., Kotti S., Hansen T.,Machecourt J., Ninio E., Tedgui A., Danchin N.,Hakan Ahlstrom, Mallat Z. Circulating levels of secretory- and lipoproteinassociated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur Heart J, 2012; 33:2946-54. †contributed equally to this work

Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-30.

Aissaoui N, Puymirat E, Tabone X, Charbonnier B, Schiele F, Lefèvre T, Durand E, Blanchard D, Simon T, Cambou JP, Danchin N.Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries. Eur Heart J. 2012;33(20):2535-43.

Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, Montely JM, Dubourg O, Tedgui A, Kotti S, Mallat Z.Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570-7

Simon T, Steg PG, Becquemont L, Verstuyft C, Kotti S, Schiele F, Ferrari E, Drouet E, Grollier G, Danchin N. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther. 2011;90(4):561-7

Lim P, Moutereau S, Simon T, Gallet R, Probst V, Ferrieres J, Gueret P, Danchin N. Usefulness of Fetuin-A and C-Reactive Protein Concentrations for Prediction of Outcome in Acute Coronary Syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction. Am J Cardiol.2013;111:31-7

Hanssen M, Cottin Y, Khalife K, Hammer L, Goldstein P, Puymirat E, Mulak G, Drouet E, Pace B, Schultz E, Bataille V, Ferrières J, Simon T, Danchin N.  French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. Heart. 2012;98:699-705.

Puymirat E, Taldir G Aissaoui  N, Lemesle G., Lorgis L., Cuisset Th., Bourlard P., Maillier B., Ducrocq G. , Ferrieres J, Simon T, Danchin N. Use of Invasive Strategy In Non-ST-Elevation Myocardial Infarction Is a Major Determinant of Improved Long-Term Survival. The FAST-MI Registry. JACC Cardiovasc Interv 2012;5(9):893-902.

Belle L, Labarère J, Fourny M, Drouet E, Mulak G, Dujardin JJ, Vilarem D, Bonnet P, Hanssen M, Simon T, Ferrières J, Danchin N; French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction study investigators. Quality of care for myocardial infarction at academic and nonacademic hospitals. Am J Med. 2012;125(4):365-73.

Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou JP, Ferrieres J, Simon T; for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. Impact of Type of Preadmission Sulfonylureas on Mortality and Cardiovascular Outcomes in Diabetic Patients with Acute Myocardial Infarction.  J Clin Endocrinol Metab. 2010;95:4993-5002

Danchin N,  Fauchier L, Marijon E, Barnay C, Furber A, Mabo Ph, Bernard P, Blanc JJ, Jouven X, Le Heuzey JY, Charbonnier B,  Ferrieres J,  Simon T . Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart 2010;96:1809-1814

Puymirat E, Aïssaoui N, Collet JP, Chaib A, Bonnet JL, Bataille V, Drouet E, Mulak G, Ferrières J, Blanchard D, Simon T, Danchin N. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry. Int J Cardiol, 2011, Nov 10. [Epub ahead of print]

Puymirat E, Aïssaoui N, Coste P, Dentan G, Bataille V, Drouet E, Mulak G, Carrié D, Blanchard D, Simon T, Danchin N. Comparison of Efficacy and Safety of a Standard Versus a Loading Dose of Clopidogrel for Acute Myocardial Infarction in Patients ≥75 Years of Age from the FAST-MI Registry. Am J Cardiol. 2011;108:755-9

Simon T, Mary-Krause M, Cambou JP, Hanania G., Guéret P., Lablanche JM, Blanchard D, Genès N, Vaur L, Danchin N on behalf of the USIC investigators. Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: increased early risk in younger women. Results from the French nation-wide USIC registries. Eur Heart J, 2006, 27 (11) : 1282-8.

Tabassome Simon discusses Clinical Pharmacology and the FAST-MI Registry

At the 11th EACPT Congress in Geneva, EACPT Vice-Chairman Professor Tabassome Simon from Paris discussed results on inflammatory mediators and outcomes of acute coronary syndromes, based on data from the French FAST-MI Registry.
In a podcast discussion with EACPT Secretary Donald Singer, Tabassome Simon discusses- the origins and significance of the FAST-MI French Registry of patients with acute coronary syndromes
- the contribution of Clinical Pharmacology to the success of FAST-MI 
- the strengths of including non-cardiological drugs in FAST-MI
- the strengths of bio-banking serological and genetic samples in FAST-MI

1. Listen to the podcast with Tabassome Simon about the origins and importance of the FAST-MI Registry.

2. Listen to Tabassome Simon discussing the role of Clinical Pharmacology in FAST-MI Registry.  Download transcript

FAST-MI collaborator Ziad Mallat with EACPT Vice-Chair Tabassome Simon and EACPT Secretary Donald Singer

Weblinks for selected FAST-MI publications


Around 600 young and senior pharmacologists and other delegates from 5 continents were in Geneva at the end of August, for the 11th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). 

More about the 11th EACPT Congress in Geneva.

Paddle steamer by Hôtel de la Paix, Geneva

View and download Congress Programme

View Congress Abstracts ONLINE at the Clinical Therapeutics website.

The Geneva Congress brought together a wide range of international delegates, including health professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. For the Geneva Congress, there were 101 invited speakers from 21 countries - 15 from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. Around 300 abstracts from 57 countries from all 5 continents were presented as oral and poster communications.

Future EACPT Congresses and Summer Schools
2014 - 11th EACPT Summer School - Nijmegen: 5-8 July
2015 - 12th EACPT Congress - Madrid
2017 - 13th EACPT Congress - Prague
2019 - 14th EACPT Congress - Stockholm  

Update from Paris on the EACPT

Late cherry blossom in Paris

The EACPT Executive Committee met in Paris 18th-20th April, hosted by EACPT Vice-Chair Professor Tabassome Simon. The main business of this EC meeting included planning for the 11th biennial EACPT congress to be held from 28^th – 31^st August 2013 in Geneva.  

EACPT biennial congresses provide excellent opportunities to showcase issues of topical international concern to the CPT community, through timely and accessible original research presentations and commentaries to policy-makers, health and industry professionals, health technology providers, patient groups and academia.

The Geneva Congress will bring together a wide range of international delegates, including health

EACPT Executive Committee at the Hôpital St Antoine in Paris

professionals, clinical and life scientists, policy makers, professionals from the biotechnology and pharmaceutical communities and others interested in the spectrum from basic to clinical pharmacology and pharmacotherapy, and from drug discovery to regulatory affairs. For the Geneva Congress, there will be 101 invited speakers from 21 countries - 15 from the European region and a further 6 countries internationally, from the USA, Canada, New Zealand, China, Benin and India. Close to 400 abstracts have been submitted from 57 countries from all 5 continents for consideration for oral and poster communications.

Marie Besson (see Figure) and Caroline Samer are leading the local organizing committee for the EACPT in Geneva. Key themes at the Geneva congress will range from bedside pharmacology for special patient groups,

Marie Besson with EACPT Chairman Gonzalo Calvo

to pharmacology & toxicology, and pharmacology and society. Further sessions will include new biological agents, translational medicine and pharmacogenetics, advances in personalised diagnostics to improve the safety and effectiveness of medicines, updates on new biological approaches to ocular disease, therapeutics of cardiovascular, cancer and inflammatory disease, clinical trial design and regulation, drug safety and toxicology, clinical trial design and governance, health policy, communicating with the public, and safe prescribing. There will also be sessions on the safety of drugs, and on the European and international regulatory environment. 

To register for the Geneva EACPT Congress, go to the Congress website.